Juan L Coelho-Silva

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1621510/publications.pdf

Version: 2024-02-01

46 papers	351 citations	840776 11 h-index	888059 17 g-index
49 all docs	49 docs citations	49 times ranked	575 citing authors

#	Article	IF	Citations
1	STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Investigational New Drugs, 2022, 40, 438-452.	2.6	6
2	Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. Investigational New Drugs, 2022, , 1.	2.6	0
3	Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells. Toxicology in Vitro, 2022, 83, 105384.	2.4	1
4	Molecular-Based Score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. Scientific Reports, 2021, 11, 1675.	3.3	2
5	NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, 2021, 39, 736-746.	2.6	7
6	Alpha thalassemia, but not Î²S-globin haplotypes, influence sickle cell anemia clinical outcome in a large, single-center Brazilian cohort. Annals of Hematology, 2021, 100, 921-931.	1.8	3
7	MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model. Cell Death and Disease, 2021, 12, 371.	6.3	5
8	Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia. Cellular Oncology (Dordrecht), 2021, 44, 1105-1117.	4.4	16
9	A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?. Leukemia and Lymphoma, 2021, 62, 147-157.	1.3	6
10	The ratio of ATP11C/PLSCR1 mRNA transcripts has clinical significance in sickle cell anemia. Annals of Hematology, 2021, , 1.	1.8	1
11	Clinical Significance of Mitochondrial DNA Content in Acute Promyelocytic Leukemia. Blood, 2021, 138, 3474-3474.	1.4	0
12	Suppression of multiple antiâ€apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Science, 2021, , .	3.9	1
13	IGF1R-IRS1/2 Pharmacological Inhibitors Act By Distinct Cellular and Molecular Mechanisms and Reveals Vulnerabilities for Treatment of Acute Myeloid Leukemia. Blood, 2021, 138, 1869-1869.	1.4	0
14	Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. Investigational New Drugs, 2020, 38, 733-745.	2.6	13
15	Association between ANXA2*5681 polymorphism (rs7170178) and osteonecrosis in haemoglobin SSâ€genotyped patients. British Journal of Haematology, 2020, 188, e8-e11.	2.5	2
16	Association of HMIP1 C-893A polymorphism and disease severity in patients with sickle cell anemia. Hematology, Transfusion and Cell Therapy, 2020, 43, 243-248.	0.2	2
17	Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia. Cellular Oncology (Dordrecht), 2020, 43, 1191-1201.	4.4	6
18	Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. Blood Advances, 2020, 4, 2339-2350.	5.2	11

#	Article	IF	Citations
19	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. Scientific Reports, 2020, 10, 10315.	3.3	5
20	NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy, 2020, 5, 5.	17.1	26
21	Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. Blood, 2020, 135, 870-875.	1.4	48
22	Irs1S57X Heterozygous Mutant Mice Display Normal Hematopoiesis and Phenotypic Features, While Homozygous Knockout Exhibit High Fetal or Postnatal Lethality. Blood, 2020, 136, 33-34.	1.4	0
23	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. Blood, 2019, 134, 951-959.	1.4	21
24	IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. Cancer Letters, 2019, 456, 59-68.	7.2	31
25	PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia. Cancer Genetics, 2019, 233-234, 56-66.	0.4	21
26	Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET). Blood, 2019, 134, 554-554.	1.4	3
27	Metformin Suppress Cellular and Molecular Processes Related to Maintenance and Proliferation of Myeloproliferative Neoplasm Stem Cell. Blood, 2019, 134, 1682-1682.	1.4	1
28	IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia. Blood, 2019, 134, 2689-2689.	1.4	0
29	MN1 Expression Is an Indepedent Prognostic Marker in FLT3-Mutated Acute Myeloid Leukemia and Is Involved in the Resistance to FLT3 Inhibitors. Blood, 2019, 134, 1403-1403.	1.4	0
30	Efficacy of the Pan-Bcl-2 Inhibitor (Obatoclax) As a Single Agent to Treat Myeloproliferative Neoplasm in JAK2V617F Murine Transplantation Model. Blood, 2019, 134, 2977-2977.	1.4	0
31	Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts. Blood, 2019, 134, 2602-2602.	1.4	0
32	Molecular-Based Score Inspired on Metabolic Signature Improves Prognostic Stratification for Myelodysplastic Syndrome. Blood, 2019, 134, 4257-4257.	1.4	0
33	Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. Blood, 2019, 134, 5166-5166.	1.4	0
34	Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. Cell Death and Disease, 2018, 9, 311.	6.3	14
35	Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival. Applied Cancer Research, 2018, 38, .	1.0	2
36	Interleukinâ€6 Gâ€174C polymorphism predicts higher risk of stroke in sickle cell anaemia. British Journal of Haematology, 2018, 182, 294-297.	2.5	1

#	Article	IF	Citations
37	Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. Clinics, 2018, 73, e566s.	1.5	35
38	Autophagy Inhibition Potentiates Ruxolitinib-Induced Apoptosis in JAK2V617F Cells. Blood, 2018, 132, 1788-1788.	1.4	0
39	Clinical Impact and Therapeutic Opportunity of Insulin Receptor Substrates 1/2 in Acute Myeloid Leukemia. Blood, 2018, 132, 1512-1512.	1.4	0
40	Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia. Haematologica, 2017, 102, e43-e46.	3.5	5
41	Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells. Heliyon, 2017, 3, e00405.	3.2	9
42	Prognostic importance of <scp>CD</scp>56 expression in intermediate risk acute myeloid leukaemia. British Journal of Haematology, 2017, 176, 498-501.	2.5	8
43	Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia. Blood Advances, 2017, 1, 1807-1814.	5.2	8
44	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. Blood Advances, 2017, 1, 86-89.	5.2	0
45	Î”Np73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype. Oncotarget, 2017, 8, 8475-8483.	1.8	3
46	High Î”Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. Blood, 2015, 126, 2302-2306.	1.4	28